Want to see ZBIO full AI Analyst Report?
ZBIO Stock Chart & Stats
$21.82
-$0.05(-0.51%)
At close: 4:00 PM EST
$21.82
-$0.05(-0.51%)
Day’s Range― - ―
52-Week Range$11.00 - $44.60
Previous CloseN/A
Volume96.53K
Average Volume (3M)900.11K
Market Cap
$1.86B
Enterprise Value$680.97M
Total Cash (Recent Filing)$717.21M
Total Debt (Recent Filing)$351.73M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 18, 2026EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.10
Shares Outstanding63,133,377
10 Day Avg. Volume1,375,331
30 Day Avg. Volume900,105
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.71
Price to Sales (P/S)162.41
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.56
Enterprise Value/Ebitda-1.67
Forecast
1Y Price Target
$41.40Price Target Upside89.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.81
Revenue Forecast (FY)$21.88M
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayA >$718M cash balance and recent financing extending runway into 2029 materially reduces near-term financing pressure. This durable liquidity supports completion of late-stage programs, potential regulatory submissions, and early commercialization planning without immediate dilutive raises.
Positive Phase 3 Data (Obexelimab)Robust 52-week Phase 3 efficacy (56% flare-risk reduction) meaningfully de-risks the obexelimab program, strengthening a potential first-in-class label. Structurally, positive pivotal data improves odds of regulatory approval, licensing interest and a commercial launch pathway that could drive sustainable future revenues.
Diversified Clinical PipelineA multi-asset portfolio across indications (autoimmune, MS, IL-17 program) spreads clinical and commercial risk. Multiple programs at different stages increase the probability of at least one successful asset, enabling medium-term growth opportunities and strategic partnership options beyond a single binary outcome.
Bears Say
Large Operating Cash BurnSustained TTM operating cash outflow (~$210M) indicates ongoing high burn to fund trials and operations. Over a multi-quarter horizon this necessitates continued financing or spending cuts; persistent burn increases dilution risk and places long-term pressure on strategic flexibility if milestones slip.
Minimal And Volatile Revenue BaseWith only $10M TTM revenue and meaningful decline year-over-year, the company lacks meaningful commercial cash flow to offset R&D spend. This structural revenue weakness prolongs reliance on external capital and means profitability is unlikely absent successful asset approvals or partnerships.
Rising Debt And LeverageRapidly increased debt (~$195M TTM) lifts fixed obligations and raises leverage (debt/equity ~0.58). While cash balances are strong today, higher debt amplifies refinancing and interest risk if cash burn continues, reducing financial optionality and increasing downside if clinical or commercial timelines slip.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $11.00 and its highest was $44.60 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $1.86B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
Zenas BioPharma, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 38 days.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on May 13, 2026. The company reported -$1.46 earnings per share for the quarter, beating the consensus estimate of -$1.474 by $0.014.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate is -1.12.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 63,133,377 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$1.46 in its last earnings report, beating expectations of -$1.474. Following the earnings report the stock price went up 4.019%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zenas BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.40 (89.73% Upside)
$41.40 (89.73% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 740.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.9%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
180.55%
12-Months-Change
Fundamentals
Return on Equity
-167.71%
Trailing 12-Months
Asset Growth
124.01%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$41.40
▲(89.73% Upside)
Technical Analysis
Ownership Overview
25.17% Insiders
22.69% Mutual Funds
<0.01% Other Institutional Investors
44.19% Public Companies and
Individual Investors